Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PFE - PFIZER INC


Close
26.7
0.220   0.824%

Share volume: 209
Last Updated: Fri 27 Dec 2024 03:30:18 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.05%

PREVIOUS CLOSE
CHG
CHG%

$26.48
0.22
0.83%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
30%
Profitability 13%
Dept financing 25%
Liquidity 75%
Performance 37%
Company vs Stock growth
vs
Performance
5 Days
0.11%
1 Month
3.76%
3 Months
-7.70%
6 Months
-2.48%
1 Year
-5.88%
2 Year
-47.70%
Key data
Stock price
$26.70
P/E Ratio 
-63.32
DAY RANGE
$26.47 - $26.48
EPS 
-$0.46
52 WEEK RANGE
$25.10 - $31.54
52 WEEK CHANGE
-$7.12
MARKET CAP 
164.388 B
YIELD 
5.63%
SHARES OUTSTANDING 
5.667 B
DIVIDEND
$0.42
EX-DIVIDEND DATE
07/26/2024
NEXT EARNINGS DATE
10/29/2024
BETA 
0.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$54,420,127
AVERAGE 30 VOLUME 
$43,161,060
Company detail
CEO: Albert Bourla
Region: US
Website: pfizer.com
Employees: 83,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health. The company also provides biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Cibinqo brands.

Recent news